Hot Topics at ASCO-GI 2022

Real‑world outcomes show survival benefit of first-line durvalumab or pembrolizumab plus gemcitabine and cisplatin in advanced biliary tract cancer.

Tinengotinib, a novel FGFR inhibitor, has the potential to overcome resistance to prior FGFR therapies in the treatment of advanced cholangiocarcinoma.

FGFR2 inhibition with lirafugratinib delivers strong responses and manageable safety in FGFR2‑altered advanced cholangiocarcinoma.

A post-hoc analysis of HERIZON-BTC-01 demonstrates improved survival outcomes in patients utilizing zanidatamab.

Ivosidenib in combination with durvalumab plus gemcitabine and cisplatin shows potential activity with minimal toxicity in patients with IDH1‑mutant cholangiocarcinoma.

Real‑world data in IDH1‑mutant cholangiocarcinoma illuminates biomarker testing trends, treatment sequencing, and survival outcomes, outlining the role of ivosidenib in second‑line care.

Adjuvant sintilimab plus capecitabine shows promising recurrence‑free survival and manageable safety in resected extrahepatic cholangiocarcinoma.

Welcome to the final edition of CCA News for this season. This end-of-season issue reflects highlights from the 2025 Cholangiocarcinoma (CCA) Summit held in Scottsdale, AZ, where international experts presented leading advances in CCA.

Groundbreaking advancements in cholangiocarcinoma research, including targeted therapies, immunotherapy innovations, and promising early detection strategies, are highlighted in this issue.